<DOC>
	<DOCNO>NCT02798692</DOCNO>
	<brief_summary>The objective first-in-human evaluate safety immunogenicity three administration bivalent vaccine candidate human cytomegalovirus , three different dose level .</brief_summary>
	<brief_title>Trial Evaluate Safety Immunogenicity Vaccine Against HCMV</brief_title>
	<detailed_description>Hookipa Biotech AG develop replication-deficient lymphocytic choriomeningitis virus ( rLCMV ) vector platform . HB-101 bivalent vaccine contain two recombinant , replication-deficient lymphocytic choriomeningitis virus ( rLCMV ) vector , one express pp65 protein human cytomegalovirus ( HCMV ) one express gB protein human cytomegalovirus ( HCMV ) . This Phase 1 enroll three successive cohort 18 healthy volunteer . Each cohort receive either low dose , middle dose high dose vaccine ( n=14 volunteer ) , placebo ( n=4 ) . A DSMB review safety data low dose cohort , progress middle , high dose . Eight DSMB meeting plan whole study . The subject follow 12 month post first administration .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Signed informed consent Male female , age 1845 year , good health . Negative HCMV Body mass index 19 32 kg/mÂ² Willing forego receipt routine vaccination ( exception seasonal influenza vaccination ) five month study entry . For female volunteer : use effective birth control least 2 month prior study entry willing use effective birth control measure Month 12 visit Comply requirement protocol ( e.g . return followup visit ) , judge Investigator . Works childcare provider . Pregnant breastfeed woman . Any screening safety laboratory value 2 time upper limit normal value . Any confirm suspected immunodeficiency autoimmune disorder . Treatment chronic immunosuppressive medication immunomodifying drug within 6 month prior study entry . However , inhaled topical steroid allow . Any vaccination seasonal influenza within 3 month prior study entry . Previous vaccination investigational HCMV vaccine . Receipt blood , blood product and/or immunoglobulin within 3 month prior study entry . History severe allergic reaction /or anaphylaxis Allergy component vaccine preparation . Expected unavailable complete study follow . Tested positive HIV , HBsAg and/or antiHCV . Participating another clinical trial . Subject rash , dermatological condition tattoo area injection site , may interfere administration site reaction rating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Prevention</keyword>
</DOC>